Related Experiment Video
Updated: Jan 16, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Direct-acting antiviral treatment significantly shaped the gut microbiota in chronic hepatitis C patients: a pilot
Nahla M Elsherbiny1, Omnia M Kamal El-Din2, Elham Ahmed Hassan3
1Medical Microbiology and Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Background:
Chronic hepatitis C (CHC) can be effectively cured with direct-acting antivirals (DAAs), yet the impact of CHC on the gut microbiota remains controversial, with limited research on changes in patients who achieve a sustained virological response (SVR) versus those who relapse.
Aim:
To investigate the impact of CHC on the gut microbiota and compare changes between patients who achieved SVR post-DAA treatment and those who relapsed.
Methods:
In this case-control study, 60 stool samples were collected from CHC patients (20 untreated, 20 post-DAAs SVR, and 20 relapsed patients) and 20 healthy individuals. The V3-V4 regions of the 16S rRNA gene were sequenced using MiSeq to analyze bacterial diversity and composition.
Results:
Compared with healthy participants, CHC patients presented significantly altered bacterial diversity. The microbial diversity of the SVR patients was similar to that of the controls (p = 0.45), whereas the microbial diversity of the relapsed patients was lower. The gut microbiota clearly clustered on the basis of disease status. Firmicutes were predominant in treated patients, whereas Bacteroidetes and Proteobacteria were enriched in the relapsed group. Compared with the other groups, the SVR group presented lower Actinobacteria and higher Cyanobacteria levels. Genus-level analysis revealed significant disease-dependent biomarkers and intermicrobial coexistence. Prevotella, Bifidobacterium, and Lactobacillus were more prevalent in relapsed patients, whereas Bacteroides, Agathobacter, and Parabacteroides were more abundant in controls. Elusimicrobium, Christensenellaceae R-7, Catenibacterium, Oceanobacillus, and Candidatus Melainabacteria were significantly more abundant in the SVR group.
Conclusion:
DAAs have a significant impact on the gut microbiota in CHC patients, resulting in distinct microbial patterns, biomarkers, and interactions. Successful HCV eradication restores bacterial diversity and reestablishes microbial communities resembling those in healthy individuals.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...

